secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0000200406-25-000110
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

JNJ Q1 adj EPS $2.77 (+2.2%), revenue $21.9B; dividend +4.8% to $1.30
---------------------------------------------------------------------

- GAAP net earnings $11.0B ($4.54 diluted EPS) vs $3.3B ($1.34), boosted by $7.3B other income.
- Adjusted net earnings $6.71B ($2.77 diluted EPS) vs $6.58B ($2.71), up 1.9% operationally.
- Worldwide sales $21.89B, up 2.4% reported, 4.2% operational; US +5.9%, International -1.8%.
- Innovative Medicine $13.87B (+2.3% reported, +4.2% op); MedTech $8.02B (+2.5% reported, +4.1% op).
- Dividend raised 4.8% to $1.30/quarter, payable June 10, 2025; record May 27, 2025; 63rd annual increase.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000020040625000110/0000200406-25-000110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000020040625000110/jnj-20250415.htm
  HTML page:      https://secwatch.observer/filing/0000200406-25-000110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer